Rhizen receives USFDA orphan drug designation for cancer drug
The US Food and Drug Administration (USFDA) has granted orphan drug designation for Tenalisib (RP6530) for the treatment of patients with peripheral T-cell lymphoma (PTCL), Alembic Pharmaceuticals said in a BSE filing.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Lymphoma | Pharmaceuticals | T-cell Lymphoma